IPOpulse
Back to Ticker

Neuland Laboratories Limited

NSE: NEULANDLAB
Healthcare Healthcare
₹19,220
-2.31%EOD · 19 Oct

Neuland Laboratories Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹24,659 Cr
52W Range
₹24225 / ₹11500
Volume
32K
51.8% delivery
1Y Return
+17.8%
P/E Ratio
50.7
P/B Ratio
13.5
Debt / Equity
16.07

Peers in Healthcare

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
Neuland Laboratories Limited(this stock)₹19,220₹24,659 Cr50.713.5—0.17%
Divi's Laboratories LimitedDIVISLAB₹9,087₹2.41 L Cr83.014.516.2%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM₹4,558.7₹1.73 L Cr72.818.417.0%0.83%
Laurus Labs LimitedLAURUSLABS₹2,069₹1.12 L Cr101.821.017.7%0.12%
Zydus Lifesciences LimitedZYDUSLIFE₹1,113.9₹1.11 L Cr25.04.218.3%0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP₹7,700₹1.11 L Cr54.312.021.5%0.25%
Aurobindo Pharma LimitedAUROPHARMA₹1,621.4₹93,292 Cr26.12.69.9%0.00%
Mankind Pharma LimitedMANKIND₹2,253.2₹93,067 Cr46.05.812.4%0.00%
Max Healthcare Institute LimitedMAXHEALTH₹830₹80,785 Cr56.77.714.3%0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice
C
44/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityWeak · 35
ValuationPoor · 20
MomentumStrong · 80
High debt load (D/E 16.1)
In confirmed uptrend (Stage 2)

Technical Indicators

Full analysis · objective math, not advice
Returns
1D
-2.3%
1W
-6.5%
1M
-15.2%
3M
+1.4%
6M
+25.7%
1Y
+17.8%
Weinstein Stage
Stage 2 — Advancing (uptrend)
RSI (14)
17 Oversold
Trend Template
6/7strong
RS vs Nifty (3M)
+6.2pp
Moving Averages (price vs MA)
20-DMA
₹21222
below
50-DMA
₹22349
below
150-DMA
₹18423
above
200-DMA
₹17225
above
From 52W High
-20.7%
From 52W Low
+67.1%
Support (20D)
₹19135
Resistance (20D)
₹23050

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.